Neumora posts J.P. Morgan investor presentation

Neumora Therapeutics, Inc. furnished a new corporate presentation that it plans to use in meetings with investors and analysts at the 44th Annual J.P.

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. furnished a new corporate presentation that it plans to use in meetings with investors and analysts at the 44th Annual J.P. Morgan Healthcare Conference. The presentation, dated January 2026, is provided as Exhibit 99.1 to this report and is incorporated into the report by reference.

The company notes that the presentation and related information are being furnished, not filed, which means they are not subject to certain liability provisions under federal securities laws and will not automatically be incorporated into other SEC documents.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Neumora Therapeutics (NMRA) disclose in this report?

Neumora Therapeutics disclosed that it made available a new corporate presentation, which it plans to use for investor and analyst meetings at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is attached as Exhibit 99.1.

What is included as Exhibit 99.1 for Neumora Therapeutics (NMRA)?

Exhibit 99.1 is a corporate presentation dated January 2026 that Neumora Therapeutics intends to use in meetings with investors and analysts at the J.P. Morgan Healthcare Conference.

Is Neumora Therapeutics’ J.P. Morgan Conference presentation considered filed with the SEC?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, and is not subject to Section 18 of the Exchange Act or Section 11 and 12(a)(2) of the Securities Act.

Will Neumora Therapeutics’ new presentation be incorporated into other SEC filings?

The company specifies that the information in the presentation and related disclosure will not be incorporated by reference into any other SEC filing, regardless of any general incorporation language in such filings.

Who signed this Neumora Therapeutics (NMRA) report?

The report was signed on behalf of Neumora Therapeutics, Inc. by Michael Milligan, the company’s Chief Financial Officer.

What other exhibit is referenced in this Neumora Therapeutics (NMRA) report?

In addition to the corporate presentation, the report references Exhibit 104, described as the Cover Page Interactive Data File embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 07:00 AM EST Learn about SEC filing dates

false 0001885522 0001885522 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

NEUMORA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41802		84-4367680
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

260 Arsenal Way, Suite 1 Watertown, Massachusetts		02472
(Address of principal executive offices)		(Zip Code)

(857) 760-0900

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		NMRA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, Neumora Therapeutics, Inc. (the “Company”) made available a corporate presentation, which it plans to use for meetings with investors and analysts at the 44^th Annual J.P. Morgan Healthcare Conference. A copy of the presentation is being furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation dated January 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				NEUMORA THERAPEUTICS, INC.
Date: January 12, 2026				By:		/s/ Michael Milligan
						Michael Milligan
						Chief Financial Officer